New pill could stop painful swelling attacks in rare disease

NCT ID NCT04618211

Completed Symptom relief Sponsor: Pharvaris Netherlands B.V. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral medication called deucrictibant for quickly relieving swelling and pain attacks in people with hereditary angioedema (HAE) types I and II. 74 adults received either one of three doses of the drug or a placebo during an attack. The main goal was to see if symptoms like skin swelling, skin pain, and belly pain improved more with the drug than with placebo within 4 hours.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

C1 inhibitor deficiency hereditary angioedema hereditary angioedema type 1 hereditary angioedema type 2 Hereditary Angioedema Types I and II hereditary angioedema with C1Inh deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C1 ESTERASE INHIBITOR DEFICIENCY C1 INHIBITOR DEFICIENCY HEREDITARY ANGIOEDEMA HEREDITARY ANGIOEDEMA - TYPE 1 HEREDITARY ANGIOEDEMA - TYPE 2 HEREDITARY ANGIOEDEMA ATTACK HEREDITARY ANGIOEDEMA TYPE I HEREDITARY ANGIOEDEMA TYPE II HEREDITARY ANGIOEDEMA TYPES I AND II HEREDITARY ANGIOEDEMA WITH C1 ESTERASE INHIBITOR DEFICIENCY

Contacts and locations

Locations

Study site

Birmingham, Alabama, 35209, United States
Study site

Paradise Valley, Arizona, 85253, United States
Study site

San Diego, California, 92122, United States
Study site

Santa Monica, California, 90404, United States
Study site

Walnut Creek, California, 94598, United States
Study site

Chevy Chase, Maryland, 20815, United States
Study site

St Louis, Missouri, 63141, United States
Study site

Hershey, Pennsylvania, 17033, United States
Study site

Sofia, Bulgaria
Study site

Edmonton, Alberta, Canada
Study site

Ottawa, Ontario, Canada
Study site

Toronto, Ontario, Canada
Study site

Montreal, Quebec, Canada
Study site

Québec, Quebec, Canada
Study site

Brno, Czechia
Study site

Hradec Králové, Czechia
Study site

Grenoble, France
Study site

Montpellier, France
Study site

Paris, France
Study site

Berlin, Germany
Study site

Dresden, Germany
Study site

Frankfurt, Germany
Study site

Mainz, Germany
Study site

Ulm, Germany
Study site

Budapest, Hungary
Study site

Ashkelon, Israel
Study site

Haifa, Israel
Study site

Tel Aviv, Israel
Study site

Monserrato, Italy
Study site

Naples, Italy
Study site

Amsterdam, Netherlands
Study site

Krakow, Poland
Study site

Barcelona, Spain
Study site

Madrid, Spain
Study site

Brighton, United Kingdom
Study site

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.